Open report — full analysis, no account required.

Sign up to generate reports and read filings that aren't on the open list.

Sign up free

Get notified when UNCY files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: UNCY Unicycive Therapeutics, Inc. 8-K

Unicycive director Gaurav Aggarwal resigns from Board, no disagreement cited

Filed April 6, 2026 · Period ending April 6, 2026 · ~1 min read

1 key change

Key Changes

  • medium

    Director Gaurav Aggarwal resigned from the Board effective April 6, 2026. The company stated the resignation was not due to any disagreement with management or the Board on operations, policies, or practices.

Summary

Unicycive Therapeutics disclosed that director Gaurav Aggarwal resigned from its Board of Directors on April 6, 2026. The company explicitly stated that Dr. Aggarwal's departure was not the result of any disagreement with management or the Board regarding the company's operations, policies, or practices—language typically included to signal an amicable separation.

For retail investors, director resignations can sometimes indicate internal concerns, but the explicit "no disagreement" language here suggests a routine departure. The company thanked Dr. Aggarwal for his service. Investors should watch for any follow-up disclosure about a replacement director or changes to Board committee composition, as well as whether the company provides additional context in its next proxy filing about the circumstances of the resignation.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify